Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: Although most studies have suggested an increased risk of valvulopathy (primarily regurgitation) with pergolide mesylate use, one study suggested that this problem may also occur with use of the non-ergot-derived dopamine agonists pramipexole dihydrochloride and ropinirole hydrochloride. Objective: To determine if cardiac valve regurgitation occurs more commonly in patients with Parkinson disease (PD) treated with pergolide than in those treated with nonergot agonists at a comparable dose. Design: A case-control study of echocardiographic findings of valve function in patients receiving dopamine agonists for PD. Setting: University-based referral center. Patients: Thirty-six patients with idiopathic PD taking pergolide were compared with a matched control group of patients taking nonergot agonists with regard to the frequency and severity of cardiac valve regurgitation. Main Outcome Measure: Valve scores (1 indicates trace; 2, mild; 3, moderate; and 4, severe) for the pergolide group were compared with those for the nonergot agonist control group. Results: The mean±SD valve regurgitation scores in the matched pergolide group compared with the nonergot group were as follows: aortic, 0.83±1.23 vs 0.19±0.53 (P=.01); mitral, 1.42±1.0 vs 0.39±0.65 (P<.001); and tricuspid, 1.43±1.0 vs 0.19±0.53 (P<.001). Lifetime exposure to a dopamine agonist was not statistically different between the pergolide and nonergot agonist groups (P=.18). Conclusions: These data strengthen the conclusion that pergolide contributes to cardiac valve regurgitation when used in the long term as a treatment for PD. There appears to be low risk of cardiac valve regurgitation when using non-ergot-derived dopamine agonists.

Original languageEnglish (US)
Pages (from-to)377-380
Number of pages4
JournalArchives of Neurology
Volume64
Issue number3
DOIs
StatePublished - Mar 2007

Fingerprint

Pergolide
Heart Valves
Parkinson Disease
Dopamine Agonists
Research Design
Control Groups
Valve
Parkinson's Disease
Case-Control Studies
Referral and Consultation
Outcome Assessment (Health Care)
Dopamine

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

@article{effde77bdf284af88a942cabf266f16d,
title = "Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease",
abstract = "Background: Although most studies have suggested an increased risk of valvulopathy (primarily regurgitation) with pergolide mesylate use, one study suggested that this problem may also occur with use of the non-ergot-derived dopamine agonists pramipexole dihydrochloride and ropinirole hydrochloride. Objective: To determine if cardiac valve regurgitation occurs more commonly in patients with Parkinson disease (PD) treated with pergolide than in those treated with nonergot agonists at a comparable dose. Design: A case-control study of echocardiographic findings of valve function in patients receiving dopamine agonists for PD. Setting: University-based referral center. Patients: Thirty-six patients with idiopathic PD taking pergolide were compared with a matched control group of patients taking nonergot agonists with regard to the frequency and severity of cardiac valve regurgitation. Main Outcome Measure: Valve scores (1 indicates trace; 2, mild; 3, moderate; and 4, severe) for the pergolide group were compared with those for the nonergot agonist control group. Results: The mean±SD valve regurgitation scores in the matched pergolide group compared with the nonergot group were as follows: aortic, 0.83±1.23 vs 0.19±0.53 (P=.01); mitral, 1.42±1.0 vs 0.39±0.65 (P<.001); and tricuspid, 1.43±1.0 vs 0.19±0.53 (P<.001). Lifetime exposure to a dopamine agonist was not statistically different between the pergolide and nonergot agonist groups (P=.18). Conclusions: These data strengthen the conclusion that pergolide contributes to cardiac valve regurgitation when used in the long term as a treatment for PD. There appears to be low risk of cardiac valve regurgitation when using non-ergot-derived dopamine agonists.",
author = "Dewey, {Richard B.} and Reimold, {Sharon C.} and O'Suilleabhain, {Padraig E.}",
year = "2007",
month = "3",
doi = "10.1001/archneur.64.3.377",
language = "English (US)",
volume = "64",
pages = "377--380",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease

AU - Dewey, Richard B.

AU - Reimold, Sharon C.

AU - O'Suilleabhain, Padraig E.

PY - 2007/3

Y1 - 2007/3

N2 - Background: Although most studies have suggested an increased risk of valvulopathy (primarily regurgitation) with pergolide mesylate use, one study suggested that this problem may also occur with use of the non-ergot-derived dopamine agonists pramipexole dihydrochloride and ropinirole hydrochloride. Objective: To determine if cardiac valve regurgitation occurs more commonly in patients with Parkinson disease (PD) treated with pergolide than in those treated with nonergot agonists at a comparable dose. Design: A case-control study of echocardiographic findings of valve function in patients receiving dopamine agonists for PD. Setting: University-based referral center. Patients: Thirty-six patients with idiopathic PD taking pergolide were compared with a matched control group of patients taking nonergot agonists with regard to the frequency and severity of cardiac valve regurgitation. Main Outcome Measure: Valve scores (1 indicates trace; 2, mild; 3, moderate; and 4, severe) for the pergolide group were compared with those for the nonergot agonist control group. Results: The mean±SD valve regurgitation scores in the matched pergolide group compared with the nonergot group were as follows: aortic, 0.83±1.23 vs 0.19±0.53 (P=.01); mitral, 1.42±1.0 vs 0.39±0.65 (P<.001); and tricuspid, 1.43±1.0 vs 0.19±0.53 (P<.001). Lifetime exposure to a dopamine agonist was not statistically different between the pergolide and nonergot agonist groups (P=.18). Conclusions: These data strengthen the conclusion that pergolide contributes to cardiac valve regurgitation when used in the long term as a treatment for PD. There appears to be low risk of cardiac valve regurgitation when using non-ergot-derived dopamine agonists.

AB - Background: Although most studies have suggested an increased risk of valvulopathy (primarily regurgitation) with pergolide mesylate use, one study suggested that this problem may also occur with use of the non-ergot-derived dopamine agonists pramipexole dihydrochloride and ropinirole hydrochloride. Objective: To determine if cardiac valve regurgitation occurs more commonly in patients with Parkinson disease (PD) treated with pergolide than in those treated with nonergot agonists at a comparable dose. Design: A case-control study of echocardiographic findings of valve function in patients receiving dopamine agonists for PD. Setting: University-based referral center. Patients: Thirty-six patients with idiopathic PD taking pergolide were compared with a matched control group of patients taking nonergot agonists with regard to the frequency and severity of cardiac valve regurgitation. Main Outcome Measure: Valve scores (1 indicates trace; 2, mild; 3, moderate; and 4, severe) for the pergolide group were compared with those for the nonergot agonist control group. Results: The mean±SD valve regurgitation scores in the matched pergolide group compared with the nonergot group were as follows: aortic, 0.83±1.23 vs 0.19±0.53 (P=.01); mitral, 1.42±1.0 vs 0.39±0.65 (P<.001); and tricuspid, 1.43±1.0 vs 0.19±0.53 (P<.001). Lifetime exposure to a dopamine agonist was not statistically different between the pergolide and nonergot agonist groups (P=.18). Conclusions: These data strengthen the conclusion that pergolide contributes to cardiac valve regurgitation when used in the long term as a treatment for PD. There appears to be low risk of cardiac valve regurgitation when using non-ergot-derived dopamine agonists.

UR - http://www.scopus.com/inward/record.url?scp=33947196215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947196215&partnerID=8YFLogxK

U2 - 10.1001/archneur.64.3.377

DO - 10.1001/archneur.64.3.377

M3 - Article

C2 - 17353380

AN - SCOPUS:33947196215

VL - 64

SP - 377

EP - 380

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 3

ER -